In order to facilitate the expansion of T cells in the B cell environment, we engineered an anti-CD19 CAR structure (CFE) on our T cells, and validation experiments were conducted on a TCR-T model with a pair of T cell receptors specifically recognizing HLA-A2/ESO1 complex on tumor cells (Figure 2A). This evidence concerns the gene CD19 and neoplasm.